A new computational tool developed by researchers has uncovered genetic evidence directly linking Alzheimer’s disease to the ...

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...

A research team at the Max Planck Institute for Chemical Ecology has successfully combined single-cell RNA sequencing (scRNA-seq) and single-cell mass spectrometry (scMS) analysis on the same plant ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced simultaneous presentation and publication of updated data from the Phase 1/2 portion of the Phase 1/2/3 ...

Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the presentation of ...

Announcement of a podium presentation at a prestigious symposium, showcasing innovative research in cell therapy for type 1 diabetes. Presentation features promising clinical data on UP421, a novel ...

A Vertex Pharmaceuticals cell therapy for type 1 diabetes is enabling patients to produce insulin, eliminating the need for additional insulin therapy in the vast majority of participants in a key ...

Tzield, a monoclonal antibody approved for stage 2 Type 1 diabetes, now seeks approval for stage 3 disease based on trial ...